Volume 7 Supplement 1

International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour

Open Access

The effects of cannabinergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety

  • Shadi Sarahroodi1,
  • Mohamma Reza Zarrindast2,
  • Ardeshir Arzi1,
  • Saba Taheri Shalmani3 and
  • Sara Mahboubi3
Annals of General Psychiatry20087(Suppl 1):S331

DOI: 10.1186/1744-859X-7-S1-S331

Published: 17 April 2008

Background

Reports indicate that cannabinergic agents can change anxiety-related behaviours in both animals and humans. The amygdala is an important brain site in the modulation of fear or anxiety.

Materials and methods

In the present study, we investigated the effects of intracentral amygdala microinjection of cannabinergic agents on anxiety-related behaviours in rats, using the elevated plus-maze test of anxiety. Intracentral amygdala administration of ACPA a cannabinergic potent agonist (0.125, 1.25,5 ng/0.5 μl bilateral) increased %open arm time and % open arm entries, but not locomotor activity, showing an anxilytic response. Intracentral amygdala microinjection of AM251 a potent CB1 antagonist (2.5, 25, 100 ng/0.5 μl bilateral) did not change anxiety-related parameters in our experiments.

Results

The results suggest that cannabinergic agonists may reduce anxiety via CB1 receptors in the rat central amygdala.

Conclusions

Couse that CB1 antagonist didn't show any effect on anxiety we think that CB1 isn't the main receptor in central amygdala.

Authors’ Affiliations

(1)
Depatment of pharmacology & toxicology, Ahvaz Jondi shapour University of Medical Sciences
(2)
Department of pharmacology, Tehran University of Medical Sciences
(3)
Departement of Biology, Azad Islamic University

Copyright

© Sarahroodi et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement